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Abstract
Cholangiocarcinoma (CCA) is a rare cancer arising 
from the biliary tree with a poor prognosis and limited 
therapeutic options. Recent large scale molecular chara-
cterisation studies have identified recurrent genetic 
alterations in CCA which may be amenable to thera-
peutic targeting. In this review we explore the genomic 
landscape of CCA and examine results from trials of 
molecularly targeted agents and immunotherapy in this 
disease. Challenges in CCA diagnosis, treatment and trial 
design are discussed and we reflect on future directions 
which may lead to improved outcomes for CCA patients. 
Key words: Cholangiocarcinoma; Biliary tract cancer; 
Targeted therapy; immunotherapy; Mutation; Molecular; 
Microenvironment; Stroma; MiRNA
© The Author(s) 2017. Published by Baishideng Publishing 
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Core tip: Cholangiocarcinoma (CCA) is a clinically 
challenging malignancy; it is rare, molecularly hetero-
genous and associated with a poor prognosis. Here we 
review recent data on the genomic landscape of CCA 
and highlight the results of clinical trials using targeted 
agents and immunotherapy. We find a number of pro-
mising therapeutic agents in development and discuss 
strategies to improve diagnosis and outcomes in this 
patient group.
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INTRODUCTION
Cholangiocarcinoma (CCA) is a relatively infrequent 
malignancy arising from epithelial cells lining the biliary 
tree. It is associated with poor prognosis and limited 
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standard therapeutic options. Globally incidence varies 
considerably according to geographical location with 
significantly higher rates in South-East Asia compared to 
Western countries. In North-East Thailand the incidence 
is high at 85 per 100000[1], whilst in the United States 
and United Kingdom the incidence is much lower 
at around 1-3 cases per 100000 population[2,3]. The 
typical age at diagnosis of CCA is around 70 years, with 
slightly higher incidence in men than women[4]. Survival 
depends on the stage of disease at presentation, but 
even in patients with localised disease, five-year survival 
is poor at 15% and 30% for intrahepatic (ICC) and 
extrahepatic (ECC) CCA respectively[5]. For unclear 
reasons the incidence of ICC is increasing in western 
countries whilst rates of ECC are falling internationally[6].
ClassIfICaTION
CCA is now classified according to anatomical location 
into ICC, perihilar and distal subtypes; the latter two 
are ECC tumours. Prior to this novel classification the 
terms intra- and extra-hepatic CCA predominated, 
and we will use this nomenclature for the purposes 
of this review. This anatomical classification is useful 
as in addition to guiding surgical management, it is 
increasingly recognised that ICC and ECC have differing 
molecular profiles and may arise from differing cells 
of origin. There is evidence to suggest that some ICCs 
arise from the hepatic stem cell lineage whilst other 
ICCs and most ECCs arise from the biliary tree stem 
cell lineage[7]. Understanding the differences in tumour 
aetiology and biology between CCA subtypes will help 
guide stratification of targeted therapies.
aeTIOlOgy
Parasitic infection with the liver flukes Clonorchis 
sinensis and Opisthorchis viverrini, which are endemic 
in parts of South-East Asia, are strongly associated 
with development of CCA. In non-Asian countries most 
cases occur sporadically, however conditions causing 
bile stasis and chronic biliary inflammation are asso-
ciated with CCA development. Specific risk factors 
include primary sclerosing cholangitis, hepatolithiasis, 
choledocal cysts and Caroli’s syndrome (congenital 
cystic dilation of intrahepatic bile ducts). All causes 
of liver cirrhosis potentially predispose to CCA and 
studies have identified viral hepatitis and alcoholic 
liver disease as specific risk factors. The now banned 
radiocontrast, thorotrast has also been associated with 
CCA development.
MaNageMeNT Of CCa 
Localised disease
Surgery and locoregional therapy: Less than 40% 
of patients present with resectable disease[8] and 5-year 
survival rate for patients with completely resected 
bile duct and GBC is in the range of 20%-50%. Loco-
regional failure occurs in more than half of patients, 
even in absence of residual disease (R0) and provides 
the justification for the study of adjuvant therapy.
Previously, the role of adjuvant chemotherapy for 
resected patients is not clearly defined. Phase III trials in 
this setting had not demonstrated a survival advantage 
in CCA, but these studies have included a range of 
tumour types (including pancreatobiliary, gallbladder 
and ampullary carcinomas) and have lacked sufficient 
power to identify a survival difference specifically 
in CCA[9,10]. However, recently the results of the UK 
BILCAP study have been presented in abstract form. 
This large phase III randomised trial recruited patients 
with resected biliary cancer including 368 (plus 79 
gallbladder carcinomas) cholangiocarcinoma patients 
and randomised between no adjuvant therapy or 6 mo 
of oral capecitabine. Patients treated with capecitabine 
had improved overall survival [53 mo vs 36 mo HR = 0.75 
(95%CI: 0.58-0.97; P = 0.028)]. The results will lead 
to adjuvant capecitabine being adopted as a standard of 
care in resected bilary cancers. 
Liver transplantation is not a standard treatment for 
CCA due historically high recurrence rates and donor 
shortage. More modern series, have reported more 
encouraging results[11]. Potential candidates, such as 
patients with poor hepatic reserve for extended hepate-
ctomy or those with localised but unresectable perihilar 
CCA should be enrolled on to suitable clinical trials.
Locoregional therapies, including radiotherapy, pho-
todynamic therapy, chemo/radio-embolisation and 
radiofrequency ablation may have a role in locally ad-
vanced disease or patients who are surgically unfit. 
There is a lack of comparative clinical trial evidence 
to support any of these modalities improving survi-
val compared to standard of care chemotherapy[12]. 
However retrospective and phase II data suggest a 
promising rate of local control by adding radiotherapy 
in the management of ICC, and warrants further investi-
gation[13,14]. 
Unresectable/metastatic disease
The United Kingdom phase 3 ABC-02 trial established 
cisplatin-gemcitabine combination therapy as standard 
of care for the first line treatment of advanced CCA, 
providing a clinically significant survival advantage 
compared to gemcitabine alone (median OS 11.7 
mo vs 8.1 mo, HR = 0.64, 95%CI: 0.52-0.80, P < 
0.001)[15]. There is currently no established second 
line treatment for advanced CCA and although a 
number of small phase II studies have shown disease 
activity, using single agent or doublet combinations of 
5-FU, oxaliplatin, and gemcitabine, this has not been 
validated in a randomised trial[16]. Results from the 
ABC-06 (NCT01926236) phase III trial, investigating 
FOLFOX chemotherapy compared to supportive care in 
the second line setting are awaited.
Pathophysiology
Desmoplastic stroma: The tumour microenviron-
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ment plays an important role in CCA pathogenesis. 
CCA bile ducts are typically surrounded by a dense 
hypovascular desmoplastic stroma, consisting of cancer 
associated fibroblasts (CAF) expressing α-smooth 
muscle actin (SMA), activated macrophages and a 
fibrotic collagen rich extracellular matrix[17]. α-SMA 
positive CAFs are involved in CCA progression and 
tumours of patients expressing high levels of α-SMA 
have poorer survival[18]. CAFs produce a range of 
factors involved in autocrine and paracrine signalling, 
promoting oncogenic processes such as proliferation, 
invasion, metastasis and apoptosis evasion. Specifically, 
the factors produced by CAFs include periostin, tenas-
cin-c, thrombospandin 1, stromal cell derived factor 
1 (SDF-1), hepatocyte growth factor (HGF) and Wnt-
inducible signalling protein-1v (WISP1)[18]. These 
factors interact with CCA cells to manipulate cell-
signalling pathways. For instance periostin interacts 
with tenascin-C, HGF and SDF-1, which bind to 
their respective receptors, integrin, MET and CXCR4 
on CCA cells, leading to activation of the PI3K/AKT 
signalling pathway. Cancer associated macrophages 
are also important in the stromal microenvironment 
and appear to have prognostic significance. In one 
study, high numbers of CD163+ macrophages in the 
stroma of resected ICC correlated with poor disease 
free survival[19]. Inflammatory macrophage infiltrates in 
CCA are also associated with increased WNT signalling, 
and abrogation of WNT signalling in preclinical models 
inhibits CCA growth[20]. In cholangiocarcinoma, sus-
tained interleukin-6 (IL-6) signalling which promotes 
tumour growth via autocrine mechanisms is also as-
sociated with increasing fibrosis and dense stroma 
formation; it is recognised that this dense hypovascular 
stroma poses a challenge to cytotoxic drug delivery[18]. 
Therefore targeting stromal factors involved in cho-
langiocarcinogenesis or improving drug delivery throu-
gh the desmoplastic stroma are attractive targets for 
novel therapeutics. 
MOleCUlaR ChaRaCTeRIsaTION aND 
pOTeNTIal fOR TaRgeTeD TheRapIes
With recent technological advances in genomic se-
quencing, the mutational landscape of CCA is increa-
singly understood. Careful evaluation is needed to 
determine which genetic aberrations are true drivers 
of CCA. This section will review recent data on key 
genetic abnormalities thought to be implicated in 
CCA pathogenesis. There are clear differences in the 
prevalence of known oncogenic driver mutations 
between ICC and ECC, implicating distinct processes 
of oncogenesis for these tumour subtypes (Table 1). 
However it is also noteworthy that the prevalence 
of mutations is highly variable across studies, this 
heterogeneity may be reflective of regional variation, 
small sample size, or differences in the pathological 
classification of ICC and ECC prior to sequencing. 
Also of interest is that liver fluke related CCA is 
associated with a differing pattern of genetic mutations 
compared to non-fluke CCA. In one of the first studies 
to sequence CCA, 8 liver fluke CCA were analysed, 
revealing novel mutations in SMAD4 (17%), MLL3 
(15%), ROBO2, GNAS and RNF (9%) each and 
CKDN2A and PEG3 (5%) each[21]. In a subsequent 
follow up study of 208 CCA cases (108 caused by liver 
fluke O. viverinni), TP53 mutations were more often 
seen in fluke related CCA, whilst IDH1/2 and BAP1 
mutations were more common in non-fluke CCA[22]. 
This highlights the impact of environmental risk factors 
on the pattern of somatic mutations. The prognostic 
value of several somatic mutations seen in CCA has 
been evaluated, however results are conflicting.
Interestingly IDH1/2 (Isocitrate dehydrogenase) 
mutations are seen almost exclusively in ICC. The IDH 
mutation results in reduced normal function of this 
enzyme and leads to increased production of 2-hydro-
xyglutarate (2-HG) from alpha-ketoglutarate. 2-HG is 
considered an oncometabolite and causes epigenetic 
changes, including histone and DNA methylation, 
which promotes tumour development[23]. In one study 
of 326 patients with resected ICC, IDH1/2 mutations 
were associated with improved overall survival[24], 
however another whole exome sequencing study (n 
= 32) suggested worse overall survival for patients 
with these aberrations (3 year OS 33% mutant vs 
81% wildtype, P = 0.003)[25], however in this study a 
higher proportion of patients with IDH mutations had 
advanced disease (50% vs 15%). Two other studies 
  Genetic mutation Frequency (%) in all tumours 
tested
Ref.
Intrahepatic 
CC
Extrahepatic 
CC
  IDH 1/2 14%-36% 0% [27,59,67,99-101]
  BAP 1 9%-25% 4%-10% [66,67,101]
  KRAS 9%-24% 40%-47% [62-64,96]
  TP53 3%-38% 18%-45% [62-64,96]
  PBRM1 11%-17% 4%-11% [63,97]
  ARID1A 11%-36% 5%-16% [62-64,95]
  EGFR amplification 7% 0% [101]
  HER2 0%-2% 0%-20% [67,101]
  VEGF overexpression 42% 31% [46,47]
  PIK3CA 4%-6% 9% [66,101]
  BRAF 4%-22% 6% [57,101-103]
  FRGR translocation 6%-50% 0%-5% [66]
  MCL1 amplification 16%-21% NR [66]
  PTEN 1%-11% 4% [59,101]
  FBXW7 1%-6% 4%-15% [67]
  CDK6 7% NR [66]
  CDKN2A 7% 15% [66]
  BRCA 1/2 4% NR [66]
  SMAD4 1%-4% 11%-25% [59,67,101]
  mTOR 26% 40% [67]
Table 1  Mutation frequency for intrahepatic and extrahepatic 
cholangiocarcinoma
HER2: Human epidermal growth factor 2; CC: Cholangiocarcinoma; NR: 
Not reported.
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examining the effect of IDH mutations in patients 
with resected and advanced ICC demonstrated no 
significant association with prognosis[26,27]. Pre-clinical 
data suggesting oncogenic addiction to IDH signalling 
can be pharmacologically abrogated resulting in 
control of cancer cell growth has been demonstrated 
in IDH mutant glioma lines[28]. Inhibitors of mutant 
IDH1 and IDH2 are currently in clinical trials (Table 
2); early results for AG-120 which is an IDH1 inhibitor 
demonstrated tolerable toxicity with evidence of 
pharmacodynamic endpoint modulation with reduced 
circulating levels of 2-hydroxyglulatrate were observed 
in most patients[29]. Of twenty CCA patients treated, 
one (5%) had a partial response whereas 11 (55%) 
had stable disease. 
The genes BAP1, ARID1A and PBRM1, which are 
involved in chromatin remodelling, have been found 
to be frequently mutated in ICC and in one study had 
inactiva ting mutations in just under half (n = 15/32) 
of ICC cases[25]. Whether these mutations can pre-
dict sensitivity to the histone deacetylase inhibitor 
vorinostat, which targets chromatin regulation has not 
yet been determined. However in a preclinical study 
vorinostat did show anti-cancer activity against the 
HuCC-T1 human CCA cell line[30]. 
Epidermal growth factor receptor alterations as a target 
in CCA
The epidermal growth factor receptor (EGFR) is abnor-
mally activated in a number of human cancers and is 
therapeutically targeted using monoclonal antibodies 
or tyrosine kinase inhibitors[31]. EGFR targeted agents 
have demonstrated clinical efficacy in non-small cell 
lung cancer (NSCLC), colorectal cancer and SCC of 
the head and neck, where they are now established 
standard therapies. In NSCLC EGFR gene mutation, 
predicts response to EGFR inhibition[32]. Both activating 
mutations and amplifications of the EGFR gene have 
been observed in CCA. EGFR mutations have been 
observed in 10%-15% of CCA[33-35], however due to 
small sample numbers data are conflicting regarding 
whether prevalence is higher in ICC or ECC. EGFR 
overexpression appears to be more prevalent in 
ICC (11%-27%) compared to ECC (5%-19%)[36,37]. 
Prognostically, EGFR expression has been found to be 
a negative predictor of overall survival in CCA[37,38], 
making this an attractive target for drug intervention. 
There have been 3 reported phase II trials investi-
gating anti-EGFR monoclonal antibodies (mABs) in 
CCA but none have demonstrated survival advantage 
in this patient group. In a single arm phase II trial of 
30 patients with advanced biliary tract cancer (aBTC) 
treated with first-line GEMOX-cetuximab, Gruenberger 
et al reported an objective response rate (CR + PR) of 
63%, mOS of 15.2 mo (9.9-20.5) and 9 patients were 
able to undergo potentially curative resection following 
systemic therapy. Whilst this trial did not have a 
control arm and patients were unselected for EGFR 
expression or KRAS status, the reported response rate 
was considered encouraging[39]. Subsequently in the 
  Title Target Phase Estimated 
sample size
Expected 
completion date
Trial number
  CX-4945 in combination with gemcitabine and cisplatin for frontline treatment 
  of CCA
Casein kinase 2 I/II   100 Dec 2016 NCT02128282
  BGJ398 in patients with advanced CCA and FGFR gene fusion FGFR gene fusion II     55 Jul 2018 NCT02150967
  Dasatanib in IDH-mutant advanced ICC II     19 Sep 2022 NCT02428855
  RRx-001 in second line treatment of advanced CCA prior to readministration 
  of first line therapy 
Epigenetic 
modifications
II     30 May 2018 NCT02452970
  ASLAN001 in advanced CCA who progressed on at least 1 line of therapy Pan-HER 
inhibitor
II     25 Dec 2017 NCT02609958
  Regorafanib as single agent in advanced CCA who failed first line Multi-kinase 
inhibitor (VEGF, 
KIT, PDGF, FGFR, 
BRAF)
II     37 Feb 2018 NCT02053376
  Copanlisib in combination with gemcitabine and cisplatin in advanced CCA PI3K inhibitor II     25 Dec 2018 NCT02631590
  LDK378 in ROS1/ALK overexpressed advanced CCA ROS1 and/or 
ALK
II     34 Jul 2018 NCT02374489
  AG120 in advanced solid tumours with IDH1 mutation IDH1 I   145 May 2016 NCT02073994
  Study of LY2801653 in advanced cancer MET inhibitor I   190  Nov 2017 NCT01285037
  ABC-08: Acelarin in combination with cisplatin in locally advanced/metastatic 
  biliary tract cancers
Nucleotide 
analogue
I     24 Sep 2018 NCT02352765
  Ramucirumab for advanced pre-treated biliary cancers VEGFR2 
antagonist
II     50 Dec 2019 NCT02520141
  Keynote-158: Pembrolizumab in participants with advanced solid tumours PD1 inhibitor II 1100 Mar 2021 NCT02628067
  Immunotherapy using TILs for patients with metastatic cancer Adoptive T-cell 
therapy
II     33 Dec 2019 NCT01174121
Table 2  Clinical trials of novel agents in cholangiocarcinoma
CCA: Cholangiocarcinoma; EGFR: Epidermal growth factor receptor; FGFR: Fibroblast growth factor receptor; IDH: Isocitrate dehydrogenase; PD1: 
Programmed death 1; TIL: Tumour infiltrating lymphocytes; VEGF: Vascular endothelial growth factor.
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phase II BINGO trial, 150 patients were randomised 
to first-line gemcitabine and oxaliplatin (GEMOX) 
with or without the addition of cetuximab[40]. Median 
overall survival was numerically shorter in the GEMOX-
cetuximab group at 11.0 mo compared to 12.4 mo 
in the GEMOX group indicating lack of benefit from 
cetuximab. Neither EGFR overexpression (18 of 77 
cases, 23%) nor KRAS mutation (14 of 75 cases, 
19%) was associated with patient outcome in either 
treatment group. More recently, Leone et al showed 
that the anti-EGFR mAb panitumumab when used in 
combination with GEMOX chemotherapy in patients 
with KRAS-WT aBTC produced no improvement in 
overall survival when compared to chemotherapy 
alone (9.9 mo vs 10.2 mo, P = 0.42)[41]. 
The small molecule EGFR tyrosine-kinase inhibitor 
erlotinib has also been investigated in advanced CCA. 
In a randomised phase III trial of 268 patients with 
aBTC (CCA, gallbladder and ampullary cancer) there 
was no significant difference in the primary end-point, 
progression free survival (PFS) in patients receiving 
GEMOX with or without erlotinib (5.8 mo vs 4.2 mo, 
HR = 0.80, 95%CI: 0.61-1.03, P = 0.83)[42]. However 
the objective response rate (CR + PR) was higher in 
the erlotinib group (40 vs 21 patients, P = 0.005) and 
in the subgroup of patients with CCA, PFS was longer 
in the erlotinib group (5.9 mo vs 3.0 mo, HR = 0.73, 
95%CI: 0.53-1.0, P = 0.049). EGFR overexpression 
was reported in 12 of 60 patients (43%) in the 
erlotinib group and of these there was 1 PR and 7 
cases of SD. In summary trials investigating anti-EGFR 
therapy in CCA have to date failed to demonstrate 
any clinically meaningful benefit over standard of 
care chemotherapy. The caveat to interpretation of 
these trials is that the inclusion of heterogenous, non-
biomarker selected groups of biliary tract cancers may 
obscure any real survival benefit in smaller patient 
subsets; biomarker selected studies might be preferred 
for this reason. 
Human epidermal growth factor 2 (HER2) or Erb-B2 
Receptor Tyrosine Kinase 2 (ERBB2) amplification is rare 
in ICC, but may be present in up to 20% of ECC[37,43] 
and this target has been successfully targeted in breast 
and gastroesophageal cancer patients. Currently 
only anecdotal reports[44] are present in the literature 
regarding responses to anti-HER2 therapy in CCA, 
however a molecularly selected trial of trastuzumab in 
conjunction with GEMOX is ongoing (NCT02836847), 
and it remains to be seen whether this approach will be 
beneficial.
Angiogenesis as a target in CCA
Vascular endothelial growth factor (VEGF) has been 
targeted therapeutically in a number of malignancies, 
with anti-VEGF monoclonal antibodies demonstrating 
efficacy in colorectal, breast and ovarian cancers, 
whilst TKIs targeting the VEGF receptor are in clini-
cal use in renal cell carcinoma and hepatocellular 
carcinoma[45].
VEGF expression is reported in around 30%-40% 
of CCAs and correlates with increased lymph node 
metastasis and poorer survival[46,47], making angio-
genesis an attractive target in CCA. Bevacizumab, 
a humanised monoclonal antibody against VEGF-A 
has been investigated in CCA. Zhu et al conducted 
a single arm phase II trial and treated aBTC patients 
with first-line GEMOX plus bevacizumab[48]. They 
reported a median PFS of 7.0 mo, mOS of 12.7 mo 
and ORR of 40%, which was considered favourable 
compared to historical controls. Similar results were 
found in a phase II trial combining gemcitabine and 
capecitabine with bevacizumab in patients with aBTC 
where a median PFS of 8.1 mo and OS of 11.3 mo was 
reported[49]. Combining VEGF and EGFR inhibition has 
not significantly improved outcomes. Lubner et al used 
a combination of bevacizumab and erlotinib in a phase 
II trial of 49 patients with aBTC[50]. This trial reported a 
PR in 6 (12.2%) patients in whom the median duration 
of response was 8.4 mo and the reported mOS was 9.9 
mo. However, overall survival in these studies (10-13 
mo) did not reasonably exceed expectations for a 
phase II population and no control arm was available 
for comparison. 
More recently disappointing results were reported 
from the randomised phase II ABC-03 trial, which 
investigated gemcitabine-cisplatin with either cediranib 
or placebo as first-line treatment of patients with 
aBTC[51]. Cediranib, a tyrosine kinase inhibitor of 
VEGFR1-3 and with additional activity against PDGF 
and c-KIT, did not improve PFS compared to the 
control group (PFS 8.0 mo vs 7.4 mo, HR = 0.93, 
95%CI: 0.65-1.35, P = 0.72) or overall survival (14.1 
mo vs 11.9 mo, HR = 0.86, P = 0.44). Response rates 
were higher for cediranib treated patients (44% vs 
19% control). An interaction between baseline PDGFbb 
levels and overall survival benefit from cediranib was 
noted; patients with PDGFbb concentrations above 
the median derived an overall survial benefit from 
cediranib (P value for interaction 0.002). 
Sorafenib, a multi-targeted TKI of VEGFR-2/3, 
PDGFR, BRAF and CRAF which may also be considered 
an anti-angiogenic agent has been investigated in CCA 
with disappointing results. As single agent therapy no 
clinically meaningful benefit was observed in 2 phase 
II trials, with reported PFS of 2.3 (range 0-12) and 3 
(95%CI: 2-4) mo respectively[52,53]. When sorafenib 
was added to gemcitabine and cisplatin chemotherapy, 
PFS and OS of 6.5 and 14.4 mo respectively was 
reported which was similar to historical controls 
using chemotherapy alone[54]. Finally a phase II trial 
combining sorafenib with erlotinib was closed early due 
to failure to meet pre-determined survival criteria and 
reported a disappointing PFS and OS of 2 (95%CI: 2-3) 
and 6 (95%CI: 3-8) mo respectively[55]. 
In summary, despite encouraging early trial results, 
therapeutic targeting of angiogenesis has not been 
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successful in CCA, although using biomarkers such as 
PDGFbb may improve patient selection in future. 
Fibroblast growth factor receptor fusions
The FGF pathway is involved in a number of cellular 
processes including proliferation, migration and an-
giogenesis. Abnormalities of this pathway have been 
implicated as driver events in carcinogenesis. In CCA, 
fibroblast growth factor receptor (FGFR) chromoso-
mal translocations producing FGFR-fusion genes 
have been reported in both ICC and ECC, but are 
much more frequent in ICC (6%-50%) than ECC 
(0%-6%) (Table 3). The fusion protein is constitutively 
activated leading to downstream signalling though 
mitogen-activated protein kinase (MAPK) and PI3K/
mTOR pathways[56]. Sia et al[57] demonstrated in a 
cohort of 107 ICC patients that FGFR2 translocations 
represented the most common actionable target dete-
cted; these occurred in 16% of patients screened; this 
prevalence has been confirmed in other series[58,59]. 
One United States study has suggested that FGFR2 
fusion in ICC is more common in females, and a Ja-
panese study has implicated viral hepatitis infection 
in this pathway[56,60], however these findings require 
validation. FGFR2 translocation in CCA may confer 
a prognostic benefit. Cancer specific survival in one 
dataset for patients harbouring FGFR2 translocations 
was superior to non-translocated tumours (123 mo 
vs 37 mo respectively)[60]. Preclinical work in cell lines 
and patient derived xenografts supports blockade 
of FGFR2 signalling in CCA as a potential effective 
therapy[56,61] and early anecdotal reports of FGFR 
inhibitor therapy in FGFR2 translocated CCA patients 
have been encouraging[62]. These promising results 
were also reflected in an interim report from a phase 
II clinical trial examining the efficacy of the pan-FGFR 
inhibitor BGJ398 in CCA patients with an FGFR abnor-
mality (NCT02150967)[63] in which of 36 patients 
eligible for assessment of response, 8 (22%) had a 
partial response and the disease control rate was 75%. 
These results compare very favourably to second 
line chemotherapy for CCA and serve to highlight the 
potential benefit of targeted therapy in appropriately 
selected patients.
Other potential targets in CCA
ROS1 gene rearrangements are seen in a number 
of cancers and result in a fusion protein with a con-
stitutively activated kinase domain that promotes 
oncogenesis. In NSCLC, ROS1 rearranged tumours 
have shown encouraging response to the ALK/MET/
ROS inhibitor Crizotinib. In CCA the prevalence of ROS1 
rearrangement is reported to be around 8%-9%[58,64]. 
Larger series are needed to determine whether pre-
valence is higher in ICC or ECC, however Neia et 
al found that in a cohort of 65 biliary tract cancer 
patients FIG-ROS1 fusions were found in 4/25 ECC, 
2/14 gallbladder carcinoma, 0/26 ICC[58]. In a murine 
allograft model of ICC the FIG-ROS fusion protein 
was shown to promote tumorogenesis and FIG-ROS 
inactivation resulted in inhibition of tumour growth[65]. 
Clinical trials are in progress to assess the efficacy of 
targeting ROS1 rearrangement in CCA (NCT02374489, 
NCT02034981).
The RAS/RAF/MEK/ERK MAPK pathway is a key 
regulator of cellular proliferation and is defective in a 
number of malignancies. 
KRAS mutations are frequent in CCA and have 
a reported incidence of 9%-47%[59,66,67]. In mouse 
models, tissue specific activation of KRAS in the 
hepatic parenchyma was found to lead to development 
of ICC[68] and this process was accelerated by the 
presence of simultaneous P53[68] or PTEN loss[69]. There 
are currently no available drugs to directly target KRAS, 
however downstream proteins can be targeted, for 
instance using MEK inhibitors. In a phase II trial of the 
MEK 1/2 inhibitor selumentinib in aBTC, 12% (3/28) 
had objective response and 56% (14/28) prolonged 
stable disease (> 16 wk) resulting in a PFS of 3.7 mo 
and OS of 9.8 mo[70].
BRAF mutations in CCA are reported to occur 
at a rate of 0-22%[71,72]. In one large study, BRAF 
V600E mutation was detected in 3% (5/159) of ICC 
cases but in no (0/149) ECC cases[71]. BRAF mutation 
showed no correlation with prognosis in this study. 
Due to the infrequent occurrence of BRAF mutation 
in CC, molecularly targeted clinical trials are difficult 
to conduct, however a phase II trial of combination 
BRAF and MEK inhibition in rare cancers is in progress 
(NCT02034110). 
Noncoding RNA abnormalities in CCA 
MicroRNAs (miRNAs) are small non-coding RNAs that 
act as negative regulators of gene expression at the 
post transcription level. They bind to the 3’ untrans-
lated region of target mRNAs causing inhibition of 
translation and mRNA degradation. miRNAs can regu-
late a number of cellular processes and their abnormal 
expression is recognised in human cancers, including 
CCA. The abnormal expression of miRNA in CCA has 
been found to impact on a number of cellular processes 
  FGFR fusion partner Frequency Ref.
  FGFR2-AHCYL 7/102 (7%) [56]
  FGFR2-BICC1 2/102 (2%) [56]
41/107 (38%) [57]
1/28 (4%) [66]
  FGFR2-PPHLN1 17/107 (16%) [57]
  FGFR2-MGEA5 1/6 (17%) [62]
  FGFR2-TACC3 1/6 (17%) [62]
1/28 (4%) [66]
  FGFR-KIAA1598 1/28 (4%) [66]
Table 3  Fibroblast growth factor receptor fusions according 
to reported frequency in cholangiocarcinoma
FGFR: Fibroblast growth factor receptor.
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involved in cell cycle progression, apoptosis and cell 
signalling. In one of the first reported studies on this 
topic Meng et al demonstrated that miR-21, miR-141, 
and miR-200b were highly over-expressed in malignant 
CCA cells, and whereas inhibition of miR-21 and miR-
200b increased sensitivity to gemcitabine, inhibition of 
miR-141 decreased cell growth[73]. Chronic inflammation 
is an important risk factor for CCA. The inflammatory 
cytokine, IL-6 has been identified as a driver of cho-
langiocarcinogenesis and has been shown to alter the 
expression of a number of miRNAs including miRNA 7a, 
370, 148a and 152[74-76]. IL-6 signalling is associated 
with increased expression of DNA methyltransferase 
(DNMT), which promotes silencing of tumour sup-
pressor genes through DNA hypermethylation. The 
miRNAs 148a and 152 are believed to regulate DNMT 
expression, as demonstrated by decreased levels of 
these miRNAs in malignant cholangiocytes in in-vitro 
and xenograft models. Crucially in cells transfected 
with these miRNAs DNMT levels were shown to 
decrease leading to reduced cellular proliferation[74]. 
In another study, in a cell culture model, miRNA 29b 
was under-expressed in CCA cell lines compared to 
normal cholangiocytes, resulting in up-regulation of 
the anti-apoptotic protein MCL-1 and allowing tumour 
cells to evade apoptosis[77]. In a further study, miRNA 
494 was shown to induce G1/S transition cell cycle 
arrest, through downregulation of cyclin dependent 
kinase 6. In cell-based and xenograft models of CCA, 
miRNA494 expression was found to be reduced and its 
upregulation reduced cellular proliferation[78]. miRNA 
26a was shown to promote proliferation of CCA cells by 
lowering levels of glycogen synthase kinase 3β (GSK-3β) 
and preventing the degradation of β-catenin, leading to 
upregulation of transcription of target genes involved 
in carcinogenesis[79]. Other miRNAs may be related to 
chemoresistance; higher levels of miR-21 and miR-200b 
are associated with resistance to gemcitabine in cell 
lines whereas the converse is true for miR-29b, miR-205 
and miR-221[80]. Selaru et al[81] have also demonstrated 
that miR-21 may be oncogenic in CCA through inhibition 
of programmed cell death 4 (PDCD4) and tissue 
inhibitor of metalloproteinases 3. As pharmacological 
manipulation of noncoding RNAs develops into a viable 
therapeutic option[82], these processes could conceivably 
be targeted in future to benefit CCA patients. 
Circulating miRNAs
Pathological diagnosis of biliary tract tumours is 
frequently challenging due to the limited cellularity 
of specimens available post ERCP and also the 
desmosplastic stroma associated with biliary tract 
cancers, making the concept of a “liquid biopsy” attrac-
tive. Differential expression of several miRNAs has 
been demonstrated between patients with CCA and 
healthy controls in both tissue and blood, miR21 is 
known to be expressed at higher levels in biliary tract 
cancers, and increasing levels are also associated with 
more advanced clinical stage and fall following surgical 
resection[83]. Wang et al[84] found that miR150 was 
significantly elevated in the plasma of ICC patients 
compared to clinical controls and could be used to 
differentiate ICC patients from volunteers with a sensi-
tivity of 81% and a specificity of 58%, which was 
enhanced when CA19.9 was used in conjunction with 
miRNA analysis. Other ciculating miRNAs of interest 
include miRNA192[85] which was also linked to more 
advanced disease and a negative prognosis and 
miR106a which is downregulated in CCA compared to 
healthy controls and has similar prognostic value[86]. 
As bile secreted by the liver though the biliary 
ducts is more freely available to sample than tissue 
this also represents a potentially useful diagnostic 
material for CCA. In bile, miRNAs are contained in 
extracellular vesicles which maintain miRNA stability. 
Li et al designed a microvesicle based miRNA panel 
which was able to differentiate CCA from other causes 
of biliary disease or obstruction with a sensitivity of 
67% and specificity of 96%[87]. The panel consisted of 
miR-191, miR-486-3p, miR-16, and miR-484, of which 
the last is the most sensitive for CCA. A Japanese study 
evaluating a larger panel of miRNAs in bile found ten 
to be upregulated in biliary tract cancer compared to 
benign biliary disease, and selected a combination of 
two (miR-9 and miR-145) as a proposed diagnostic 
biomarker with a specificity of 100% and high sensi-
tivity[88]. Voigtländer et al[89] performed a study com-
paring miRNA expression in both serum and bile in 
German patients with primary sclerosing cholangitis 
and CCA, in addition to the serum of healthy controls. 
Interestingly, distinct miRNA profiles differentiated 
PSC and CCA in bile and in serum. In serum, lower 
levels of miR-1281, miR-126, miR26a, miR30b and 
miR-122 were found in CCA patients compared to 
PSC and healthy controls, whereas in bile changes 
in miR-412, miR-640, miR-1537 and miR-3189 
predominated. Unfortunately as paired samples from 
each patient were not available a predictive panel 
containing blood and bile biomarkers was unable to be 
generated, however in future such an approach could 
be of significant utility. Although the use of circulating 
miRNAs is of significant interest, these studies are 
relatively small and require validation before becoming 
clinically applicable. Furthermore consideration of the 
geographic region of origin of each of the above studies 
(impacting on CCA aetiology and biology) must be 
considered before generalising these findings.
Immunotherapy
Immune checkpoint inhibitors: Immune check-
points, which provide co-stimulatory and co-inhibitory 
signals to T-cells are exploited by a number of cancers 
to evade the host immune system and checkpoint 
inhibition has been used therapeutically, most notably 
in melanoma and non-small cell lung cancer amongst 
other malignancies. There may also be a role for 
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checkpoint inhibition in CCA. Ye et al[90] studied the 
expression of the co-inhibitory immune checkpoint, 
Programmed Death Ligand 1 (PD-L1) in 31 surgically 
resected ICC samples from Asian patients and found 
PD-L1 expression to be upregulated in tumour tissue 
compared to adjacent tissue. Tumours with high 
levels of PD-L1 expression were associated with poor 
differentiation, higher TNM stage and higher levels 
of apoptotic CD8+ tumour infiltrating lymphocytes 
(TIL). Poorer survival has also been demonstrated 
in Western patients with ICC with positive tumour 
PD-L1 expression[91,92]. Sabbatino et al[92] also found 
that downregulation of HLA class I antigen expression 
by tumour cells was associated with poorer clinical 
outcome. These data indicate PD-L1 upregulation 
and HLA class I antigen downregulation may be 
mechanisms of immune escape in CCA and could be 
potential biomarkers of response to anti-PD1/PDL1 
immunotherapy. Chemotherapy may also have a 
role in modulating the immune system via inducing 
immunogenic cell death and upregulating expression 
of tumour associated antigens. Koido et al[93] found 
treatment of ICC cells with gemcitabine resulted in 
upregulation of the tumour antigen WT1, calreticulin 
(a protein that provides a pro-phagocytic signal) and 
PD-L1. Thus there may be a rationale for combining 
standard chemotherapy drugs with immune checkpoint 
inhibitors. 
Trials investigating immune checkpoint inhibitors in 
CCA are in progress but early signals of efficacy have 
recently been reported. Keynote-028 is a multicohort 
phase Ib trial of pembrolizumab in PD-L1 positive pre-
treated advanced solid tumours[94]. Early data from the 
biliary tract cohort of this trial reported an objective 
response rate of 17% (n = 4/17, all partial responses) 
and a further 17% (n = 4/17) achieved stable disease. 
Responses appeared to be durable with all responding 
patients remaining on treatment at 40-42 wk. Le et 
al[95] also reported data from a phase II trial of 17 
patients with mismatch repair deficient non-colorectal 
gastrointestinal cancers treated with the PD-1 inhibitor 
pembrolizumab. Of the 3 patients with CCA there was 
one complete response, one partial response and one 
stable disease, with durable and ongoing responses at 
median follow up of 5.3 mo. More mature data with 
larger sample sizes are eagerly awaited but mismatch 
repair deficiency appears to be a promising predictive 
biomarker for checkpoint inhibition (although of rela-
tively rare prevalence). The Keynote-158 phase II 
trial is recruiting 1100 patient with advanced solid 
tumours to be treated with pembrolizumab and will 
include a cohort of patients with biliary tract cancer 
(NCT02628067).
Mutation specific adoptive T-Cell therapy: The 
use of T-cells with specificity to cancer antigens is an 
emerging field and efficacy has been demonstrated in 
metastatic melanoma[96] and B cell leukaemia[97]. T-cell 
based therapy for epithelial malignancies, such as CCA 
is under investigation.
Tran et al[98] treated a female patient with meta-
static CCA who had progressed on multiple lines of 
chemotherapy, with autologous TH1 tumour infiltrating 
lymphocytes (TILs) specific to a mutated antigen 
expressed by the patient’s cancer. In this novel 
approach, TILs from the patient’s lung metastases 
were retrieved and whole exome sequencing per-
formed on tumour tissue to identify somatic muta-
tions present. Further testing revealed that CD4+ TH1 
TILs recognised mutated erbb2 interacting protein 
(ERBB2IP) in the tumour tissue. These mutation 
specific TILs were clonally expanded and the patient 
underwent lymphodepletive chemotherapy, before 
receiving 42.4 billion TILs (25% ERBB2IP-mutation 
reactive T cells). There was impressive reduction in 
size of metastatic lesions and prolonged stable disease 
for more than 1 year. When the disease progressed 
after 13 mo the patient was retreated and again 
achieved disease response. Whilst this demonstrated 
an important proof of concept for T-cell based therapy 
in CCA, reproducibility in further patients is needed. 
Furthermore the highly personalised nature of this 
approach has high cost implications.
CONClUsION
CCA is a molecularly heterogeneous malignancy with 
currently limited treatment options beyond first line 
systemic chemotherapy. Genomic profiling studies have 
highlighted differing patterns of mutation signatures 
between ICC and ECC, helping to stratify patients for 
targeted therapies. FGFR fusions and IDH mutations 
appear to be frequently mutated in ICC and hold 
promise as therapeutic targets. Immunotherapy also 
has considerable potential but requires a validated 
biomarker to guide selection of patients for this appro-
ach. Circulating miRNAs are of interest in improving 
early diagnosis and detecting disease relapse. However 
given the relative rarity of this cancer and the molecular 
heterogeneity, multi-centre collaboration is essential 
in order to design adequately powered clinical trials of 
targeted agents.
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